[Clinical observations with aripiprazole in schizophrenia].
The atypical antipsychotic aripiprazole was administered once a day by peroral dose--10-15 mg--in 103 schizophrenics; they were hospitalized or in day-hospital or outpatient department. During the simple blind clinical trial it was compared by 70 schizophrenics administered by haloperidol treatment (9-15 mg/day dose). The aripiprazole had good therapeutic effect at the positive and negative symptoms of acute schizophrenia, and at the other antipsychotic non-responder patients, and had no serious side-effects. The hypothesis, that of aripiprazol had good effect on the mesolimbic dopamine system as dopamine antagonist, causes improvement on positive symptoms; also good effect on the mesocortical dopamine system as partial agonist, causes improvement on negative symptoms of schizophrenia. The patients had good compliance with aripiprazol.
Gaszner
Péter
P
Országos Pszichiátriai es Neurológiai Intézet. h12890gas@ella.hu
D000284:Administration, Oral; D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D000068180:Aripiprazole; D004334:Drug Administration Schedule; D005260:Female; D006220:Haloperidol / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D010349:Patient Compliance; D010879:Piperazines / Q000627:therapeutic use*; D015363:Quinolones / Q000627:therapeutic use*; D012559:Schizophrenia / Q000188:drug therapy*; D016037:Single-Blind Method; D016896:Treatment Outcome
D014150:Antipsychotic Agents; D010879:Piperazines; D015363:Quinolones; D000068180:Aripiprazole; D006220:Haloperidol